Aoki Y, Fukumoto Y, Inoue K, Katsuura Y, Komoriya K, Miyamoto S
Pharmacological Research Department, Teijin Institute for Bio-Medical Research, Tokyo, Japan.
Arzneimittelforschung. 2000 Aug;50(8):695-9. doi: 10.1055/s-0031-1300275.
Protein C (PC) is the zymogen of an anticoagulant serine protease and is converted to its active form (activated protein C: APC) by thrombin in the presence of thrombomodulin. APC plays an important role in regulating blood coagulation and fibrinolysis by inhibiting not only blood coagulation factors Va and VIIIa but also type-1 plasminogen activator inhibitor (PAI-1). In this study, it was reported that the antithrombotic effect of a human APC product (designated as CTC-111) compared with that of heparin and human PC on the deep venous thrombosis (DVT) model induced in mice by stasis caused by inferior vena cava ligation and operative invasion. Drugs were injected into a tail vein at -2, 30, 60, and 120 min after the inferior vena cava ligation. One-fifth amount of the total dosage of a given drug was injected at each time point. The wet weight of thrombus formed was reduced by APC or heparin administration, however, PC, which was equal to APC in protein amount, did not show any antithrombotic effect. To confirm whether human PC could be activated by mouse thrombin, PC was treated with mouse or human thrombin to measure the amount of APC formed. Mouse thrombin could activate human PC at a similar activation rate as human thrombin. These results suggest that externally administrated PC cannot exhibit antithrombotic effect in this DVT model due to slow activation rate to APC and that APC is a better antithrombic agent than PC for treating thrombotic diseases.
蛋白C(PC)是一种抗凝丝氨酸蛋白酶的酶原,在血栓调节蛋白存在的情况下,被凝血酶转化为其活性形式(活化蛋白C:APC)。APC通过不仅抑制凝血因子Va和VIIIa,还抑制1型纤溶酶原激活物抑制剂(PAI-1),在调节血液凝固和纤维蛋白溶解中发挥重要作用。在本研究中,报道了一种人APC产品(命名为CTC-111)与肝素和人PC相比,对下腔静脉结扎和手术侵袭引起的淤滞诱导的小鼠深静脉血栓形成(DVT)模型的抗血栓作用。在下腔静脉结扎后-2、30、60和120分钟,将药物注入尾静脉。在每个时间点注射给定药物总剂量的五分之一。给予APC或肝素后,形成的血栓湿重减轻,然而,蛋白量与APC相等的PC没有显示出任何抗血栓作用。为了确认人PC是否能被小鼠凝血酶激活,用小鼠或人凝血酶处理PC以测量形成的APC量。小鼠凝血酶能以与人凝血酶相似的激活速率激活人PC。这些结果表明,在该DVT模型中,外源性给予的PC由于向APC的激活速率缓慢而不能表现出抗血栓作用,并且APC是比PC更好的治疗血栓性疾病的抗血栓药物。